3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
29
Neoplasms
14
Breast Neoplasms
8
Fallopian Tube Neoplasms
7
Prostatic Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Melanoma
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Diseases
1
Pancreatic Neoplasms
1
Ovarian Diseases
1
Osteosarcoma
1
Neuroblastoma
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hereditary Sensory and Autonomic Neuropathies
1
Interventions
Bevacizumab
27
Leucovorin
23
Fluorouracil
22
Oxaliplatin
17
Irinotecan
15
Cetuximab
14
pembrolizumab
11
IFL protocol
11
Panitumumab
10
Folfox protocol
10
Capecitabine
10
Gemcitabine
7
adagrasib
5
Cisplatin
5
Carboplatin
5
Ramucirumab
4
Colonoscopy
4
veliparib
3
spartalizumab
3
selpercatinib
3
regorafenib
3
labetuzumab
3
durvalumab
3
conatumumab
3
cemiplimab
3
Pemetrexed
3
Paclitaxel
3
HMPL-013
3
Drug Therapy
3
5,11-methenyltetrahydrohomofolate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Colonic Neoplasms
×
niraparib
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts